New Directions in Angioedema: A Focus on Supportive Care and Treatment Options Sep 11, 2009
This activity is supported by an educational grant from ViroPharma Incorporated. Timothy J. Craig, DO, from the Pennsylvania State University College of Medicine in Hershey, Pennsylvania, and Aleena Banerji, MD from Massachusetts General Hospital in Boston, Massachusetts, serve as the Editorial Board for this newsletter series. (PR Newswire)
GSK seems to dismiss HGS rumour Aug 27, 2009
27 on talk that potential predator Teva Pharmaceuticals would instead turn its intentions on US antiviral maker ViroPharma. Commodities producers led the wider market lower. (FT.com -- Markets)
FDA recommendation goes against ViroPharma Aug 7, 2009
8 million for ViroPharma during the first half of this year, is used to treat severe and often life-threatening bacterial infections of the gastrointestinal tract ... We're appreciative that the FDA convened this advisory committee to provide a forum for open debate and discussion regarding a serious public health issue, said Vincent J. Milano, ViroPharma's president and CEO. While we're disappointed with the vote, we hope that the OGD will take every precaution to ensure that patients will be... (Philadelphia Business Journal, PA)
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride Aug 5, 2009
- ViroPharma and Leading Experts Voiced Concern About Process for Developing Bioequivalence ... Aug. 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: ) today announced that the Pharmaceutical Science and Clinical Pharmacology Advisory Committee supports the FDA's Office of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin(R) (vancomycin hydrochloride) capsules ... ViroPharma scientists and other leading experts voiced their concern that these new guidelines... (PR Newswire)
Bulls Avert Selloff Despite Ugly Jul 30, 2009
Existing users please login. Remember me on this computer. (Fox News)
FDA wants another study of ViroPharma drug Jun 5, 2009
FDA wants another study of ViroPharmas Cinryze - Philadelphia Business Journal ... FDA wants another study of ViroPharmas Cinryze ... The news sent ViroPharma shares 8 percent lower Thursday to $6. (Philadelphia Business Journal, PA)
ViroPharma: FDA wrong on generic testing Mar 19, 2009
ViroPharma: FDA wrong on generic Vancocin testing - Philadelphia Business Journal ... ViroPharma: FDA wrong on generic Vancocin testing ... continued its opposition to a proposal by the that sets forth rules for companies seeking to make a generic version of ViroPharma s Vancocin. (Philadelphia Business Journal, PA)
ViroPharma ends maribavir study Feb 14, 2009
Shares in ViroPharma, whose lead drug is the antibiotic Vanocin, closed 5 percent lower Friday at $6. 23. (Philadelphia Business Journal, PA)
Roche's antiviral meets main goal in late-stage study Feb 14, 2009
On Friday, American biopharmaceutical company ViroPharma Inc (VPHM.O) said it stopped a late-stage trial testing its experimental candidate, maribavir, for the same disease, four days after it said the drug failed in a prior late-stage study. (Reporting by Vidya L Nathan in Bangalore; Editing by Amitha Rajan). (Reuters)
NEW RESEARCH FOCUSES ON CURE FOR COMMON COLD... Feb 13, 2009
While the new findings are "an interesting piece of science," said Dr. Glenn Tillotson, an expert on antiviral drugs at Viropharma in Exton, Pennsylvania, he noted that the typical cost of developing a new drug was now $700 million, "with interminable fights with financiers and regulators.". Today in Health & Science. (The Drudge Report)
Study vexes ViroPharma investors Feb 10, 2009
Disappointing study results vex ViroPharma investors - Philadelphia Business Journal ... Disappointing study results vex ViroPharma investors ... -based ViroPharma (NASDAQ:VPHM) said there was no statistically significant difference from a placebo in maribavir s ability to reduce cytomegalovirus in bone marrow transplant patients. (Philadelphia Business Journal, PA)
